G.J.L.B. is an EMBO and Novartis Foundation Research Fellow. We thank Katrin Gutbrodt for her help in histology and immunofluorescence experiments, Dr. Kathrin Zuberbühler and Nadine Pasche for their help during therapy experiments, and Dr. Eveline Traschel for treating tumor-bearing mice with IgG(F8). Financial contribution from ETH Zürich, Swiss National Science Foundation, SwissBridge/Stammbach Stiftung, Kommission für Technologie und Innovation (KTI) and Philochem AG is gratefully acknowledged.
A Traceless Vascular-Targeting Antibody–Drug Conjugate for Cancer Therapy†
Version of Record online: 15 DEC 2011
Copyright © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Angewandte Chemie International Edition
Volume 51, Issue 4, pages 941–944, January 23, 2012
How to Cite
Bernardes, G. J. L., Casi, G., Trüssel, S., Hartmann, I., Schwager, K., Scheuermann, J. and Neri, D. (2012), A Traceless Vascular-Targeting Antibody–Drug Conjugate for Cancer Therapy. Angew. Chem. Int. Ed., 51: 941–944. doi: 10.1002/anie.201106527
- Issue online: 17 JAN 2012
- Version of Record online: 15 DEC 2011
- Manuscript Received: 14 SEP 2011
- ETH Zürich
- Swiss National Science Foundation
- SwissBridge/Stammbach Stiftung
- Kommission für Technologie und Innovation (KTI)
- Philochem AG
Detailed facts of importance to specialist readers are published as ”Supporting Information”. Such documents are peer-reviewed, but not copy-edited or typeset. They are made available as submitted by the authors.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.